Please sign in to follow a disease.
Hereditary nephritis
MONDO:0005334A group of inherited conditions characterized initially by hematuria and slowly progressing to renal insufficiency. The most common form is the Alport syndrome (hereditary nephritis with hearing loss) which is caused by mutations in genes for type IV collagen and defective glomerular basement membrane.
Also known as: hereditary nephritis, familial nephritis, nephritis, familial
151 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New drug aims to slow kidney damage in rare alport syndrome
Disease control Not yet recruitingThis study tests a drug called exaluren in 24 people aged 12 and older with Alport syndrome caused by specific genetic errors. The drug is given as a daily shot for 32 weeks. Half the group starts exaluren right away, while the other half gets a placebo first and then switches to…
Phase: PHASE2 • Sponsor: Eloxx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Engineered immune cells take aim at childhood autoimmune diseases
Disease control Not yet recruitingThis early-phase trial tests a single infusion of universal CAR-T cells (RD06-05) in 30 children and adolescents with severe autoimmune diseases, including lupus, scleroderma, and kidney inflammation. The cells are designed to target and calm overactive immune cells. The main goa…
Phase: EARLY_PHASE1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug trial aims to protect Kids' kidneys from IgA nephropathy
Disease control Not yet recruitingThis phase 3 trial tests the drug atrasentan in 28 children aged 2 to 18 with IgA nephropathy, a kidney disease that can lead to kidney failure. The study measures whether atrasentan reduces protein in the urine, a sign of kidney damage, over 36 weeks. All participants receive th…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug BHV-1400 aims to protect kidneys in IgA nephropathy
Disease control Not yet recruitingThis Phase 3 trial tests whether BHV-1400 can safely reduce protein in the urine and preserve kidney function in 420 adults with IgA nephropathy. Participants are randomly assigned to receive either the drug or a placebo by injection. The main goal is to see if BHV-1400 lowers pr…
Phase: PHASE3 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New pill aims to slow kidney disease in IgA nephropathy patients
Disease control Not yet recruitingThis study tests an experimental drug called STL303 for people with IgA nephropathy, a kidney disease. About 15 adults will receive either STL303 or a placebo to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage. Possible side effects include na…
Phase: PHASE2 • Sponsor: Sitala Bio LTD • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New hope for kidney patients: drug aims to prevent relapse
Disease control Not yet recruitingThis study tests whether a 15-month course of Nefecon can prevent proteinuria relapse in 288 adults with IgA nephropathy who have already achieved remission. Participants must have completed prior Nefecon therapy and have stable kidney function. The goal is to see if maintenance …
Phase: PHASE4 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug aims to protect kidneys in IgA nephropathy patients
Disease control Not yet recruitingThis study tests the long-term safety of HRS-5965 capsules in 380 adults with primary IgA nephropathy, a kidney disease. Participants will take the drug and be monitored for side effects, as well as changes in urine protein and kidney function. The goal is to see if HRS-5965 can …
Phase: PHASE2 • Sponsor: Chengdu Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug SLN12140 aims to control kidney disease in IgA nephropathy patients
Disease control Not yet recruitingThis Phase 2 trial tests SLN12140, an experimental drug, in 48 adults with IgA nephropathy whose disease is not well-controlled by standard treatments. Participants receive different doses of SLN12140 or a placebo for 36 weeks, then all can receive the drug for another year. The …
Phase: PHASE2 • Sponsor: Linno Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Swiss study to track new kidney drug in 50 patients
Disease control Not yet recruitingThis study will follow 50 adults with IgA nephropathy who are taking sparsentan. Researchers want to see how the drug affects protein in the urine (albuminuria), a key sign of kidney damage. The study is observational, meaning it just watches what happens in real-world use, witho…
Sponsor: Waid City Hospital, Zurich • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Experimental cell therapy targets kidney disease
Disease control Not yet recruitingThis early-phase trial is testing a new cell therapy called GT719 for several immune-mediated kidney diseases, including IgA nephropathy and membranous nephropathy. The therapy uses specially engineered immune cells to target and potentially control the disease. The study will en…
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New triple combo aims to tackle Hard-to-Treat liver cancer
Disease control Not yet recruitingThis phase 2 trial tests a combination of two drugs (Benmelstobart and Anlotinib) plus targeted radiation (SBRT) in 29 adults with liver cancer that has spread to a few other spots and no longer responds to first-line treatment. The goal is to see if this triple therapy can slow …
Phase: PHASE2 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Engineered immune cells aim to tame Hard-to-Treat kidney disease
Disease control Not yet recruitingThis early-phase study tests a new treatment using specially engineered immune cells (CD19 CAR-γδ T cells) for people with severe autoimmune kidney diseases like lupus nephritis, IgA nephropathy, and membranous nephropathy that haven't responded to standard therapies. About 15 pa…
Phase: EARLY_PHASE1 • Sponsor: Air Force Military Medical University, China • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for kidney disease: experimental drug targets protein leak
Disease control Not yet recruitingThis early-stage trial tests a drug called NM8074 in 10 adults with IgA Nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the drug safely reduces protein in the urine, a sign of kidney damage, after 99 days of treatment. Participants must have a…
Phase: PHASE2 • Sponsor: NovelMed Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug aims to reduce kidney damage in IgAN patients
Disease control Not yet recruitingThis study tests an experimental drug called FXS6837 in 60 adults with IgA nephropathy, a kidney disease. Participants will receive either the drug or a placebo for about 6 months. The main goal is to see if the drug lowers protein in the urine, a sign of kidney damage.
Phase: PHASE2 • Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug aims to slow kidney damage in IgA nephropathy
Disease control Not yet recruitingThis Phase 2 trial tests an experimental drug called HS-10542 in 90 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. Participants will receive either a high dose, low dose, or placebo for a set period. The main goal is to see if the drug reduces prot…
Phase: PHASE2 • Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New injection shows promise for kidney disease patients
Disease control Not yet recruitingThis study tests an investigational drug called LP-005 in 46 adults with complement-mediated kidney disease, a condition where the immune system attacks the kidneys. Participants receive the injection alongside their standard care. The goal is to see if the drug can reduce protei…
Phase: PHASE2 • Sponsor: Longbio Pharma • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Can herbal granules protect kidneys in IgA disease?
Disease control Not yet recruitingThis study tests whether Shenqi Yishen Granules, a traditional Chinese medicine, can reduce protein in the urine of adults with IgA nephropathy, a kidney disease. Researchers will compare the granules to a placebo in 102 participants over several months. The goal is to see if the…
Phase: NA • Sponsor: Keda Lu • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New injection aims to tame kidney disease
Disease control Not yet recruitingThis Phase 2 study tests an injectable drug called CM313 in 106 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if CM313 is safe and can help control the disease by reducing kidney damage. Participants will receive either CM313 or…
Phase: PHASE2 • Sponsor: Keymed Biosciences Co.Ltd • Aim: Disease control
Last updated Jun 26, 2026 18:51 UTC
-
Scientists investigate mysterious loin pain in kidney disease
Knowledge-focused Not yet recruitingThis study looks at what changes occur in the kidneys, urine, and blood when people with IgA nephropathy (IgAN) experience loin pain. Researchers will use MRI scans and lab tests to compare findings during a pain episode and when pain-free. The goal is to better understand the ca…
Sponsor: University of Leicester • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
ER study aims to uncover hidden kidney problems in kids
Knowledge-focused Not yet recruitingThis study will observe 50 children (ages 1 month to 18 years) who come to the emergency room with kidney-related symptoms like swelling, blood in urine, or high blood pressure. Researchers want to learn which kidney diseases are most common and how children respond to initial tr…
Sponsor: Sohag University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New study to track how kidney disease drugs work in real life
Knowledge-focused Not yet recruitingThis study will observe 80 adults with IgA nephropathy who are prescribed iptacopan or atrasentan as part of their routine care. Researchers will collect data on patient profiles, treatment patterns, and clinical outcomes over 24 months. The goal is to understand how these drugs …
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
New kidney drug trial aims to find safe doses for patients
Knowledge-focused Not yet recruitingThis early-stage study tests a single injection of RG002C0106 in 24 adults to see how kidney function affects the drug's levels and safety. Participants have either normal kidneys or mild-to-moderate kidney impairment. The goal is to gather basic information, not to treat the dis…
Phase: PHASE1 • Sponsor: Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
30,000 blood samples could revolutionize rapid disease testing
Knowledge-focused Not yet recruitingThis study will collect blood samples from 30,000 adults in the UK with various health conditions, including blood clots, infections, heart disease, diabetes, and more. The samples will be used to develop and fine-tune new diagnostic tests for the cobas® lumira device, which allo…
Sponsor: LumiraDx UK Limited • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC